ArticleFrontiers in nutrition2022
Sucralose, a Non-nutritive Artificial Sweetener Exacerbates High Fat Diet-Induced Hepatic Steatosis Through Taste Receptor Type 1 Member 3.
Article in Frontiers in nutrition, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 32 citations in OpenAlex.
- Long-term artificial sweetener exposure increases the risk of atherosclerosis.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Mutual Influence of Sucralose and Bisphenol A on Biological and Neurobehavioral Action inInternational journal of molecular sciences · 2026Article
- Sugar reduction in complex food systems: linking metabolic mechanisms, matrix engineering, and safety evaluation.NPJ science of food · 2026Review
- High sucralose exposure in early pregnancy increases the susceptibility of heart defects in mice offspring.iScience · 2026Article
- Long-term sucralose exposure accelerates ovarian aging via gut microbiota dysbiosis.NPJ science of food · 2026Article
- Re-evaluation of sucralose (E 955) as a food additive and evaluation of a new application on extension of use of sucralose (E 955) in fine bakery wares.EFSA journal. European Food Safety Authority · 2026Article
- Artificial and natural non-nutritive sweeteners drive divergent gut and genetic responses across generations.Frontiers in nutrition · 2026Article
- Sucralose as a Way to Enhance Regulatory T Cells, the SWEET Trial: Clinical Research Protocol.Canadian journal of kidney health and disease · 2026Article
- The non-synthetic sweeteners, miraculin and mogroside V, but not stevia, disrupt the intestinal epithelial barrier function through a sweet taste receptor-dependent mechanism.Scientific reports · 2025Article
- Biological and Behavioral Responses ofInternational journal of molecular sciences · 2025Article
- Potential Effects of Low-Calorie Sweeteners on Human Health.Nutrients · 2025Review
- Review
- New Insights into the Interplay Between Simple Sugars and Liver Diseases.Current issues in molecular biology · 2025Review
- Expression and structural analysis of taste receptor genes in Iberian and Duroc pigs.Genetics, selection, evolution : GSE · 2025Article
- Rediscovering Sweetness: The Evolution and Impact of Non-Nutritive and Natural Sweeteners.Current nutrition reports · 2025Review
- Food sweeteners: Angels or clowns for human health?Current research in food science · 2025Review
- Article
- Chronic Use of Artificial Sweeteners: Pros and Cons.Nutrients · 2024Review
- Could Insulin Be a Better Regulator of Appetite/Satiety Balance and Body Weight Maintenance in Response to Glucose Exposure Compared to Sucrose Substitutes? Unraveling Current Knowledge and Searching for More Appropriate Choices.Medical sciences (Basel, Switzerland) · 2024Review
- Sucralose: From Sweet Success to Metabolic Controversies-Unraveling the Global Health Implications of a Pervasive Non-Caloric Artificial Sweetener.Life (Basel, Switzerland) · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease globally, and it is strongly associated with obesity. To combat obesity, artificial sweeteners are often used to replace natural sugars, and sucralose is one of the most extensively used sweeteners. It was known that sucralose exerted effects on lipid metabolism dysregulation, and hepatic inflammation; however, the effects of sucralose on hepatic steatosis were still obscure. In this study, we found that supplements of sucralose enhanced high-fat-diet (HFD)-induced hepatic steatosis. In addition, treatment of sucralose increased reactive oxygen species (ROS) generation and induced endoplasmic reticulum (ER) stress in HepG2 cells. Pretreatment of ROS or ER stress inhibitors reversed the effects of sucralose on lipogenesis. Furthermore, pretreatment of taste receptor type 1 membrane 3 (T1R3) inhibitor or T1R3 knockdown reversed sucralose-induced lipogenesis in HepG2 cells. Taken together, sucralose might activate T1R3 to generate ROS and promote ER stress and lipogenesis, and further accelerate to the development of hepatic steatosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.